688428 诺诚健华
已收盘 01-14 15:00:01
资讯
新帖
简况
每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股
证券之星 · 01-11
每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股
诺诚健华：公司营业收入2025年前三季度实现加速增长
证券日报 · 01-07
诺诚健华：公司营业收入2025年前三季度实现加速增长
诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%
证券之星 · 01-06
诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%
诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组
人民财讯 · 01-02
诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组
每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位
证券之星 · 01-02
每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位
打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片
新京报 · 2025-12-31
打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片
诺诚健华(09969)授出140万份受限制股份单位
智通财经 · 2025-12-31
诺诚健华(09969)授出140万份受限制股份单位
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”
智通财经 · 2025-12-24
国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”
诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验
美股速递 · 2025-12-23
诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 2025-12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验
智通财经 · 2025-12-19
港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
华夏时报网 · 2025-12-18
奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察
诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验
美股速递 · 2025-12-18
诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
证券之星 · 2025-12-16
12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
每日经济新闻 · 2025-12-16
创新药概念再度走低 诺诚健华(09969.HK)跌超5%
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
证券日报 · 2025-12-15
诺诚健华：截至2025年11月28日A股股东户数约1.79万户
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
美股速递 · 2025-12-14
诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
智通财经 · 2025-12-14
诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点
港股诺诚健华涨超3%
每日经济新闻 · 2025-12-12
港股诺诚健华涨超3%
加载更多
公司概况
公司名称：
诺诚健华医药有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。
发行价格：
11.03
{"stockData":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.07,"timestamp":1768374001000,"preClose":22.27,"halted":0,"volume":9665013,"delay":0,"changeRate":-0.009,"floatShares":268000000,"shares":1764999999,"eps":-0.1302,"marketStatus":"已收盘","change":-0.2,"latestTime":"01-14 15:00:01","open":22.33,"high":22.66,"low":21.77,"amount":215000000,"amplitude":0.04,"askPrice":22.07,"askSize":320,"bidPrice":22.06,"bidSize":7,"shortable":0,"etf":0,"ttmEps":-0.1302,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":22.27,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":24.5,"lowLimit":20.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1764643952,"isCdr":false,"pbRate":5.84,"roa":"--","roe":"--","epsLYR":-0.26,"committee":-0.595238,"marketValue":38946000000,"turnoverRate":0.036,"status":1,"afterMarket":{"amount":0,"volume":0,"close":22.07,"buyVolume":0,"sellVolume":0,"time":1768376037558,"indexStatus":"已收盘 01-14 15:30:00","preClose":22.27},"hkstockBrief":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.07,"timestamp":1768378086007,"preClose":13.26,"halted":0,"volume":6829912,"delay":0,"premium":"-47.05"},"floatMarketCap":5923000000},"requestUrl":"/m/hq/s/688428","defaultTab":"news","newsList":[{"id":"2602553569","title":"每周股票复盘：诺诚健华（688428）股本无变动，两股权激励计划剩余可授出股份共1417.645万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602553569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602553569?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:40","pubTimestamp":1768070417,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，诺诚健华报收于22.57元，较上周的20.52元上涨9.99%。本周，诺诚健华1月9日盘中最高价报22.85元。本周关注点公司公告汇总：截至2025年12月31日，诺诚健华总股本未变，已发行股份无增减。公司公告汇总：2023年及2024年人民币股激励计划合计剩余可授出14,176,450股。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","688428","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2601806825","title":"诺诚健华：公司营业收入2025年前三季度实现加速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806825","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601806825?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:36","pubTimestamp":1767792974,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，诺诚健华在互动平台回答投资者提问时表示，公司营业收入2025年前三季度实现加速增长，公司对全年业绩目标的达成充满信心，全年业绩请关注公司按期披露的业绩预告及定期报告。二级市场股价受多种因素影响，请您注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611756388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","09969"],"gpt_icon":0},{"id":"2601139718","title":"诺诚健华（688428）披露证券变动月报表，1月6日股价下跌2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601139718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601139718?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:20","pubTimestamp":1767709235,"startTime":"0","endTime":"0","summary":"截至2026年1月6日收盘，诺诚健华报收于20.92元，较前一交易日下跌2.65%，最新总市值为369.16亿元。公司近日发布公告，披露截至2025年12月31日的证券变动月报表。已发行股份总数无变动，其中港股上市股份为1,496,284,235股，包括1,493,798,235股已发行股份和2,486,000股库存股；科创板上市人民币股份为268,359,717股。公司存在两项股权激励计划：2023年人民币股激励计划剩余可授出4,531,250股，2024年人民币股激励计划剩余可授出9,645,200股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600042473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","161027","09969","BK0239"],"gpt_icon":0},{"id":"2600037932","title":"诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2600037932","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600037932?lang=zh_cn&edition=full","pubTime":"2026-01-02 09:22","pubTimestamp":1767316966,"startTime":"0","endTime":"0","summary":"【诺诚健华新型TYK2抑制剂Soficitinib治疗特应性皮炎III期注册临床研究完成患者入组】诺诚健华今日宣布，公司自主研发的新型TYK2抑制剂soficitinib（ICP-332）的临床研究获得重大进展，治疗中重度特应性皮炎（AD）的III期注册临床试验已完成患者入组，标志着soficitinib解决AD疾病迈出了关键一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601023607534023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK4134","III","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2600039998","title":"每周股票复盘：诺诚健华（688428）授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039998","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039998?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:05","pubTimestamp":1767297912,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，诺诚健华报收于21.44元，较上周的22.2元下跌3.42%。本周，诺诚健华12月23日盘中最高价报22.67元。诺诚健华当前最新总市值362.1亿元，在化学制药板块市值排名12/150，在两市A股市值排名527/5181。本周关注点公司公告汇总：诺诚健华根据2023年股权激励计划授出合计1,400,000份受限制股份单位。公司公告汇总诺诚健华医药有限公司于2025年12月31日根据2023年股权激励计划授予两名雇员参与者合计1,400,000份受限制股份单位，约占公司已发行股份总数的0.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2595705107","title":"打卡北京小巨人｜诺诚健华总监：中国创新药几乎成为世界创新名片","url":"https://stock-news.laohu8.com/highlight/detail?id=2595705107","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595705107?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:59","pubTimestamp":1767193140,"startTime":"0","endTime":"0","summary":"\n 诺诚健华企业传播执行总监陆春华表示：“中国创新药的知识产权授权给了国际的MNC公司，今年上半年的总的对外授权的总金额，已经达到了600亿美元，超过了2024年... [全文]\n","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2025/12/31/5670566291698688769.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1767193147129723.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1767193147129723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["BK1161","688428","159992","BK1574","06978","09969","BK0239"],"gpt_icon":0},{"id":"2595727116","title":"诺诚健华(09969)授出140万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2595727116","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595727116?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2025年12月31日，公司根据2023年股权激励计划授予两名承授人140万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1574","09969","688428","BK1161"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","002755","688062","LU1997244956.HKD","LU2495084118.USD","06978","BK1589","LU1328615791.USD","000661","603087","02509","LU1146622755.USD","688428","LU2148510915.USD","09995","BK0239","LU2097828474.EUR","03692","LU0405327494.USD","LU1997245094.SGD","688336","BK0057","BK0196","688331","01801","LU2097828631.EUR","LU1781817850.SGD","01530","BK1574","BK0188","BK1161","LU1064130708.USD","BK1593","LU2097828557.USD","LU2097828714.EUR","LU2097828805.USD","600276","02142","LU0502904849.HKD","LU2580892862.HKD","LU2488822045.USD","BK0012","BK0060","BK0183","01167","LU0405327148.USD","BK0028","LU1997245177.USD","LU1969619763.USD","02096"],"gpt_icon":0},{"id":"2593342479","title":"国元国际：给予诺诚健华(09969)目标价16.81港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2593342479","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593342479?lang=zh_cn&edition=full","pubTime":"2025-12-24 14:58","pubTimestamp":1766559522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，预计诺诚健华2025-27年收入分别为人民币20.1亿、20.6亿、25.6亿元，净利润分别为人民币1.17亿、0.17亿、1.88亿元，公司持有现金及等价物约72亿元，现金足够进行创新研究。根据DCF模型，给予目标价16.81港元，给予买入评级，较现价有28%的升幅。CDE已批准启动奥布替尼治疗SLE的III期临床试验，预计2026年第一季度首例患者入组。Zenas支付1亿美元现金首付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","09969"],"gpt_icon":0},{"id":"1143469039","title":"诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1143469039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143469039?lang=zh_cn&edition=full","pubTime":"2025-12-23 18:02","pubTimestamp":1766484152,"startTime":"0","endTime":"0","summary":"诺诚健华宣布获得NMPA批准，开展Tyk2抑制剂ICP-488治疗皮肤性狼疮的二期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2148510915.USD","LU1064131003.USD","688331","688235","LU2488822045.USD","LU1064130708.USD","688428","BK0239"],"gpt_icon":0},{"id":"2592134408","title":"港股异动 | 诺诚健华(09969)涨超4% 自研新型TYK2抑制剂ICP-332治疗CSU获批准开展II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2592134408","media":"智通财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592134408?lang=zh_cn&edition=full","pubTime":"2025-12-19 11:17","pubTimestamp":1766114258,"startTime":"0","endTime":"0","summary":"消息面上，12月18日，据诺诚健华官微消息，公司宣布，自主研发的新型TYK2抑制剂soficitinib治疗慢性自发性荨麻疹获国家药品监督管理局药品审评中心批准开展II/III期临床试验。Soficitinib是诺诚健华自主研发的高效、高选择性的新型口服TYK2抑制剂，开发用于治疗多种T细胞相关的自身免疫性疾病，目前开发的适应症深度布局皮肤科这一广阔的市场，包括特应性皮炎、白癜风、结节性痒疹、荨麻疹等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","III","688428","09969","BK0239","BK4134"],"gpt_icon":0},{"id":"2592201369","title":"奥布替尼SLE临床试验突破背后 诺诚健华单产品依赖隐忧｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2592201369","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592201369?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:03","pubTimestamp":1766041380,"startTime":"0","endTime":"0","summary":"12月15日，生物医药公司诺诚健华宣布，其核心产品奥布替尼用于治疗系统性红斑狼疮（SLE）的IIb期临床研究达到主要终点，并已获国家药品监督管理局批准开展Ⅲ期临床试验。这一进展虽标志着该药在开拓自身免疫疾病这一巨大新市场的道路上迈出关键一步，但其通往成功商业化的道路仍布满不确定性，或将面临来自临床试验、市场竞争及公司战略的多重严峻挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595356395.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595356395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","688428","SLE","159992","BK1574","BK4077","06978","09969","BK0239"],"gpt_icon":0},{"id":"1162325715","title":"诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1162325715","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162325715?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:50","pubTimestamp":1766022610,"startTime":"0","endTime":"0","summary":"诺诚健华宣布在中国获批新型Tyk2抑制剂Soficitinib用于慢性自发性荨麻疹的II/III期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688428"],"gpt_icon":0},{"id":"2591097566","title":"12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591097566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591097566?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870568,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日诺诚健华跌6.09%，收盘报22.5元，换手率2.81%，成交量7.55万手，成交额1.72亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元，最新净值3.1742，较上一交易日下跌3.71%，近一年上涨34.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK1161","BK0239","BK1574","688428"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","688428","09969","BK0239","06978","159992"],"gpt_icon":0},{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","09969","BK1574","688428","BK1161","399300","159982"],"gpt_icon":0},{"id":"1121316255","title":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1121316255","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121316255?lang=zh_cn&edition=full","pubTime":"2025-12-14 17:50","pubTimestamp":1765705817,"startTime":"0","endTime":"0","summary":"诺诚健华宣布Orelabrutinib在SLE的二期临床试验中达到主要终点，并获批三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK0239"],"gpt_icon":0},{"id":"2591665068","title":"诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591665068?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:27","pubTimestamp":1765700828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(简称“SLE”)的IIb期临床研究达到主要终点，并获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展III期注册性临床试验。公司将尽快启动该临床研究。临床IIb结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性、良好的耐受性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","BK0239","BK1161","688428","BK1574"],"gpt_icon":0},{"id":"2590257886","title":"港股诺诚健华涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590257886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590257886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:21","pubTimestamp":1765520510,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)涨超3%，截至发稿，涨3.24%，报14港元，成交额5105.45万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590068918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590068918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK1161","688428","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768428300606,"stockEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":-0.0789},{"period":"3month","weight":-0.1039},{"period":"6month","weight":-0.2788},{"period":"1year","weight":0.8331},{"period":"ytd","weight":0.0755}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诺诚健华医药有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18100人(较上一季度增加0.00%)","perCapita":"14826股","listingDate":"2022-09-21","address":"Ogier Global(Cayman)Limited 89 Nexus Way Camana Bay Grand Cayma KY1-9009 Cayman Islands","registeredCapital":"0万元","survey":" 诺诚健华医药有限公司的主营业务是创新药的研发、生产及商业化。公司的主要产品是奥布替尼、坦昔妥单抗、ICP-248、ICP-B02。公司2023年被认定为国家级专精特新“小巨人”企业。","listedPrice":11.03},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,688428,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(688428)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(688428)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}